Ball Jack 4

What Happened
Jack Ball, a director of Cytek Biosciences, had 43,973 restricted stock units (RSUs) vest on June 10, 2026 and those RSUs converted into 43,973 shares of common stock. The Form 4 records an acquisition of 43,973 shares via conversion (derivative code M) and a simultaneous disposition of 43,973 shares at $0.00 (derivative). No cash value is reported for the disposition line.

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 12, 2026 (timely filing under Section 16 rules).
• Transaction codes: M = exercise/conversion of a derivative (RSU settlement).
• Shares acquired: 43,973 (conversion of RSUs). Shares disposed: 43,973 at $0.00 (reported as derivative disposal).
• Reported monetary value: acquisition N/A; disposition $0.00 per share (total $0 reported).
• Footnotes: F1 — each RSU equals a contingent right to one share; F2 — 100% of the RSU award vested on June 10, 2026.
• Shares owned after transaction: not specified in the provided filing.

Context
This filing reflects settlement of RSUs rather than an open‑market buy or sale. It is common for RSU settlements to show a simultaneous transfer or withholding of shares (often to satisfy tax withholding obligations) — the $0.00 disposition line may represent such mechanics, though the filing does not specify the purpose. No purchase or market sale is reported that would indicate a directional trading signal.